Peng-Jun Lu1, David Yankey2, Jenny Jeyarajah2, Alissa O'Halloran2, Laurie D Elam-Evans2, Philip J Smith2, Shannon Stokley2, James A Singleton2, Eileen F Dunne3. 1. Immunization Services Division, National Center for Immunization and Respiratory Diseases, and lhp8@cdc.gov. 2. Immunization Services Division, National Center for Immunization and Respiratory Diseases, and. 3. Division of Sexually Transmitted Disease Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, & TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: In 2011, the Advisory Committee for Immunization Practices (ACIP) recommended routine use human papillomavirus (HPV) vaccine for male adolescents. METHODS: We used the 2013 National Immunization Survey-Teen data to assess HPV vaccine uptake (≥1 dose) and series completion (≥3 doses). Multivariable logistic regression analysis and a predictive marginal model were conducted to identify independent predictors of vaccination among adolescent males aged 13 to 17 years. RESULTS: HPV vaccination coverage with ≥1 dose was 34.6%, and series completion (≥3 doses) was 13.9%. Coverage was significantly higher among non-Hispanic blacks and Hispanics compared with non-Hispanic white male adolescents. Multivariable logistic regression showed that characteristics independently associated with a higher likelihood of HPV vaccination (≥1 dose) included being non-Hispanic black race or Hispanic ethnicity; having mothers who were widowed, divorced, or separated; having 1 to 3 physician contacts in the past 12 months; a well-child visit at age 11 to 12 years; having 1 or 2 vaccination providers; living in urban or suburban areas; and receiving vaccinations from >1 type of facility (P < .05). Having mothers with some college or college education, having a higher family income to poverty ratio, living in the South or Midwest, and receiving vaccinations from all sexually transmitted diseases/school/teen clinics or other facilities were independently associated with a lower likelihood of HPV vaccination (P < .05). CONCLUSIONS: Following recommendations for routine HPV vaccination among male adolescents, uptake in 2013 was low in this population. Increased efforts are needed to improve vaccination coverage, especially for those who are least likely to be vaccinated.
BACKGROUND: In 2011, the Advisory Committee for Immunization Practices (ACIP) recommended routine use human papillomavirus (HPV) vaccine for male adolescents. METHODS: We used the 2013 National Immunization Survey-Teen data to assess HPV vaccine uptake (≥1 dose) and series completion (≥3 doses). Multivariable logistic regression analysis and a predictive marginal model were conducted to identify independent predictors of vaccination among adolescent males aged 13 to 17 years. RESULTS:HPV vaccination coverage with ≥1 dose was 34.6%, and series completion (≥3 doses) was 13.9%. Coverage was significantly higher among non-Hispanic blacks and Hispanics compared with non-Hispanic white male adolescents. Multivariable logistic regression showed that characteristics independently associated with a higher likelihood of HPV vaccination (≥1 dose) included being non-Hispanic black race or Hispanic ethnicity; having mothers who were widowed, divorced, or separated; having 1 to 3 physician contacts in the past 12 months; a well-child visit at age 11 to 12 years; having 1 or 2 vaccination providers; living in urban or suburban areas; and receiving vaccinations from >1 type of facility (P < .05). Having mothers with some college or college education, having a higher family income to poverty ratio, living in the South or Midwest, and receiving vaccinations from all sexually transmitted diseases/school/teen clinics or other facilities were independently associated with a lower likelihood of HPV vaccination (P < .05). CONCLUSIONS: Following recommendations for routine HPV vaccination among male adolescents, uptake in 2013 was low in this population. Increased efforts are needed to improve vaccination coverage, especially for those who are least likely to be vaccinated.
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Jessica Hughes; Joan R Cates; Nicole Liddon; Jennifer S Smith; Sami L Gottlieb; Noel T Brewer Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-03 Impact factor: 4.254
Authors: Laurie D Elam-Evans; David Yankey; Jenny Jeyarajah; James A Singleton; Robinette C Curtis; Jessica MacNeil; Susan Hariri Journal: MMWR Morb Mortal Wkly Rep Date: 2014-07-25 Impact factor: 17.586
Authors: Erin M Kahle; Elissa Meites; R Craig Sineath; Muazzam Nasrullah; Kristina E Bowles; Elizabeth DiNenno; Patrick S Sullivan; Travis Sanchez Journal: Sex Transm Dis Date: 2017-01 Impact factor: 2.830
Authors: Megan C Lindley; Jenny Jeyarajah; David Yankey; C Robinette Curtis; Lauri E Markowitz; Shannon Stokley Journal: Hum Vaccin Immunother Date: 2016-03-22 Impact factor: 3.452
Authors: Kalyani Sonawane; Ryan Suk; Elizabeth Y Chiao; Jagpreet Chhatwal; Peihua Qiu; Timothy Wilkin; Alan G Nyitray; Andrew G Sikora; Ashish A Deshmukh Journal: Ann Intern Med Date: 2017-10-17 Impact factor: 25.391
Authors: Carmen H Logie; Ashley Lacombe-Duncan; Philip Baiden; Peter A Newman; Suchon Tepjan; Clara Rubincam; Nick Doukas; Farid Asey Journal: BMJ Open Date: 2018-04-20 Impact factor: 2.692